Bloomberg - Oct. 23 (Bloomberg) -- Speedel Holding AG, the Swiss biotechnology company that developed a hypertension drug with Novartis AG, will continue work on a diabetic kidney disease treatment that triggered safety concerns in a trial last year. Another ...